tiprankstipranks
Janux Therapeutics, Inc. (JANX)
NASDAQ:JANX
US Market
JANX
Janux Therapeutics Inc
RESEARCH TOOLSreports
Want to see JANX full AI Analyst Report?

Janux Therapeutics Inc (JANX) Stock News & Sentiment

719 Followers
Janux Therapeutics: Buy Rating Reiterated as PSMA Pipeline Progress and Strong Cash Position Support Unchanged $45 Price Target
Premium
Ratings
Janux Therapeutics: Buy Rating Reiterated as PSMA Pipeline Progress and Strong Cash Position Support Unchanged $45 Price Target
10d ago
JANX
Analyst Reiterates Buy on Janux Therapeutics, Citing Deep Pipeline Catalysts and Compelling Risk/Reward at Near-Zero Enterprise Value
Premium
Ratings
Analyst Reiterates Buy on Janux Therapeutics, Citing Deep Pipeline Catalysts and Compelling Risk/Reward at Near-Zero Enterprise Value
13d ago
JANX
Analyst Reiterates Buy on Janux, Citing Pipeline Upside and Key 2027 Catalyst; Price Target Maintained at $14
Premium
Ratings
Analyst Reiterates Buy on Janux, Citing Pipeline Upside and Key 2027 Catalyst; Price Target Maintained at $14
14d ago
JANX
Janux Therapeutics: Strong Balance Sheet and Advancing PSMA Pipeline Underpin Buy Rating and Favorable Risk-Reward
Premium
Ratings
Janux Therapeutics: Strong Balance Sheet and Advancing PSMA Pipeline Underpin Buy Rating and Favorable Risk-Reward
14d ago
JANX
Janux Therapeutics Adjusts Board Class Structure for Director
Premium
Company Announcements
Janux Therapeutics Adjusts Board Class Structure for Director
23d ago
8K
JANX
Janux’s JANX011 First‑in‑Human Study: Early Safety Readout Could Shape Autoimmune Upside
Premium
Company Announcements
Janux’s JANX011 First‑in‑Human Study: Early Safety Readout Could Shape Autoimmune Upside
28d ago
JANX
Advancing PSMA Franchise and Validating TRACTr Platform Underpin Buy Rating on Janux Therapeutics
Premium
Ratings
Advancing PSMA Franchise and Validating TRACTr Platform Underpin Buy Rating on Janux Therapeutics
29d ago
JANX
More JANX News >

JANX News on the Web

STATE STREET CORP Reduces Stake in Janux Therapeutics Inc
GuruFocus News
Bearish
Insider Sell: Maria Dobek Sells Shares of Janux Therapeutics Inc (JANX)
GuruFocus News
Neutral
Janux Therapeutics price target lowered to $22 from $23 at Evercore ISI
TipRanks News
Neutral
Janux Therapeutics: Buy Rating Reiterated as PSMA Pipeline Progress and Strong Cash Position Support Unchanged $45 Price Target
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), Rocket Pharmaceuticals (RCKT) and Evolent Health (EVH)
TipRanks News
Neutral
Janux Therapeutics price target lowered to $36 from $45 at Wedbush
TipRanks News
Bearish
Wedbush Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)
TipRanks News
Bullish
Guggenheim Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
JANX
Sector Average
Media Buzz
This Week1 articles
Weekly Average7.5 articles
News Sentiment
This Week19%
Sector Average77%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is JANX’s Media Buzz Sentiment?
1 articles about JANX were published this week. In an average week, 7.5 articles are published.
    What is JANX’s weekly average amount of articles?
    In an average week, 7.5 articles about JANX are published.
      What is JANX’s News Sentiment?
      19% of articles about JANX were positive this week, compared to its sector average of 77%.
        Healthcare Stocks that are Trending in the News
        RLAYRelay Therapeutics
        GOSSGossamer Bio
        IMVTImmunovant
        ROIVRoivant Sciences
        PROKProKidney
        Showing the stocks with the most bullish news sentiment over the past week